Analysis of the JBR10 trial demonstrates a larger survival benefit associated with adjuvant chemotherapy than previously understood, providing a benchmark as novel adjuvant therapies are explored.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Seminars in Thoracic and Cardiovascular Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group.J Clin Oncol. 2008; 26: 3552-3559
- Disparities in guideline-concordant treatment for pathologic N1 non-small cell lung cancer.Ann Thorac Surg. 2020; 109: 1512-1520
Toubat O.D.L., Ding K., et al: Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell cancer is unrecognized: A subgroup analysis of the JBR10 trial. Semin Thorac Cardiovasc Surg In press.
- Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.N Engl J Med. 2005; 352: 2589-2597
- Osimertinib in resected EGFR-mutated non-small-cell lung cancer.N Engl J Med. 2020; 383: 1711-1723
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial.Lancet. 2021; 398: 1344-1357
Published online: November 15, 2022
Publication stageIn Press Journal Pre-Proof
Classification: Invited commentary
Funding: No funding was received for this work.
Conflicts of Interest: None
© 2022 Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trialSeminars in Thoracic and Cardiovascular Surgery
- PreviewAdjuvant chemotherapy is underutilized in clinical practice, in part, because its anticipated survival benefit is limited. We evaluated the impact of AC on overall and recurrence-free survival among completely resected pN1 NSCLC patients enrolled in the North American Intergroup phase III (JBR10) trial. A post-hoc subgroup analysis of pN1 NSCLC patients was performed. Participants were randomized to cisplatin+vinorelbine (AC) (n = 118) or observation (n = 116) following complete resection. The primary endpoint was overall survival (OS).